Home » FDA Committee Votes in Favor of Dyax Lead Drug for Rare Blood Disease
FDA Committee Votes in Favor of Dyax Lead Drug for Rare Blood Disease
An FDA advisory committee recommended approval of Cambridge, MA-based Dyax’s lead drug candidate, ecallantide, to treat severe attacks of a rare blood disease known as hereditary angioedema, according to an FDA spokeswoman.
Xconomy
Xconomy
Upcoming Events
-
07May
-
14May
-
30May